Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) announced better-than-expected revenue in Q3 CY2025, with sales up 1.4% year on year to $384 million. The company’s full-year revenue guidance of $1.5 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.27 per share was in line with analysts’ consensus estimates.
Lantheus Holdings (LNTH) appears undervalued with strong fundamentals. Its low P/E ratio, robust profitability, and healthy balance sheet make it a compelling value investing candidate.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital,
and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Lantheus Holdings (LNTH) appears undervalued with a low P/E ratio of 8.11, strong profitability, and a healthy balance sheet, presenting a potential value opportunity.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
jumped 2.5% in the morning session after it announced an exclusive licensing agreement with GE HealthCare to bring its prostate cancer imaging agent, PYLARIFY, to Japan.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including Lantheus (NASDAQ:LNTH) and its peers.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Lantheus Holdings (LNTH) is a value stock with a low P/E ratio, strong financial health, and high profitability, making it an attractive opportunity for value investors.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 3.1% on continued negative momentum after a downgrade by Truist Securities, which cited concerns over competitive pressures and weaker-than-expected second-quarter results. The downgrade from "Buy" to "Hold" by Truist Securities included a significant price target reduction to $63 from $111.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 4.7% in the afternoon session after Truist Securities downgraded the stock from a "Buy" to a "Hold" rating and slashed its price target by over 43%. The downgrade, which cut the price target to $63 from $111, was driven by concerns over the performance of Lantheus's key radiopharmaceutical product, PYLARIFY. This follows the company's disappointing second-quarter results, where it missed both revenue and earnings estimates. Revenue fell 4.1% year-over-year to $378 million due to competitive pricing pressures. Compounding the issue, Lantheus also lowered its full-year financial guidance for revenue and earnings, signaling expectations for continued headwinds. The combination of missed Q2 targets, a reduced outlook, and the subsequent analyst downgrade has soured investor sentiment.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 4.1% year on year to $378 million. The company’s full-year revenue guidance of $1.49 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.57 per share was 6.3% below analysts’ consensus estimates.
